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ABSTRACT 
Intestinal transplantation is often the only alternative form of treatment for 
patients dependent on total parenteral nutrition for survival. Although a limited 
number of intestinal transplantations have been performed, results with FK 
506 immunosuppression are comparable to those for other organ transplants. 
The impact of successful intestinal transplantation on gastroenterology will 
likely be similar to the impact of kidney and liver transplantation on nephrol-
ogy and hepatology. 
THE DEVELOPMENTAL PHASE 
The First Attempts 
Lillehei first reported an experimental model for isolated intestinal transplanta-
tion in dogs in 1959 (1). The first description of multivisceral canine transplan-
tation (liver, stomach, pancreaticoduodenal complex, small and large intestine) 
(2) followed a year later. 
Despite advances in immunosuppression that permitted other organ trans-
plantations, transplantation of the intestine and related organs was not clini-
cally successful. Results of clinical trials using azathioprine and cyclosporin 
(CyA), for example, proved dismal. Of all isolated intestinal transplantation 
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attempts, only two clinical cases (Kiel, Paris) (3, 4) enjoyed a long-term 
survival under CyA immunosuppression, although multiple rejections and 
assorted complications kept the patients hospitalized for prolonged periods of 
time. 
Following the multi visceral transplantations, one patient (Pittsburgh) (5) 
survived for more than six months before dying of lymphoproliferative dis-
ease, and a patient in Innsbruck (6) lived for almost a year before succumbing 
to metastases from an underlying disease. However, in each of these cases, the 
intestinal component of the grafts provided life-supporting function and al-
lowed independence from total parenteral nutrition (TPN), thereby proving the 
feasibility, but not the practicality, of intestinal transplantation in humans. 
The Concept a/Transplantation 0/ Organ Clusters 
The intraabdominal organs resemble the residual grapes of a grape cluster (7, 
8). The central stem of the vine consists of the celiac axis, the superior 
mesenteric artery, the superior mesenteric vein, and the portal vein. The or-
gans, like grapes, can be removed without disturbing the integrity of the vine. 
Thus, when various organs are removed from the multivisceral graft, the 
remaining organs constitute a custom complex that satisfies the needs of the 
patient. In addition, including the liver with the graft protects other organs 
transplanted from the same donor against rejection (2, 9). 
The cluster concept is of practical value. Because the intraabdominal organs 
have an intimate anatomical and physiological relationship, they must often be 
replaced in combinations that do not include bowel. Such procedures have 
been used to treat massive upper abdominal malignancies that necessitated 
upper abdominal excnterations (resection of the liver, stomach, spleen, pan-
creaticoduodenal complex, and frequently, parts of the ascending and trans-
verse colon). Previously, graft replacement was usually accomplished with a 
cluster containing the liver and pancreaticoduodenal complex. The duodenum 
and at times part of the jejunum served as conduits. These intestinal pieces 
proved durable, subject to rejection, and capable of regeneration even after 
severe rejection. 
APIVOTALCASE Atthe University of Western Ontario, Grantet aI reported the 
unequivocal success of a liver-small intestinal cluster transplant that enabled 
the recipient to resume normal activity without parenteral nutrition (10). These 
results were attributed to the protective effect of the contemporaneously trans-
planted liver. Consequently, the intestinal transplant was initially considered 
successful only in combination with a liver transplant. 
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INTESTINAL TRANSPLANTATION UNDER FK 506 
IMMUNOSUPPRESSION 
The current era of intestinal transplantation began with clinical trials under FK 
506 immunosuppression (11). FK 506 is a macrolide antibiotic derivative from 
the fungus Streptomyces tsukubaensis. Its immunosuppressive action is sim-
ilar in nature (although much more potent) to that of CyA, but the chemical 
structures of the two differ, and FK 506 binds to a different immunophilin 
(12). Although FK 506 and CyA share some side effects (nephrotoxicity, 
neurotoxicity, diabetogenicity), FK 506 does not cause gingival hyperplasia or 
hirsuitism and has absorption characteristics superior to those of CyA (13). 
Clinical trials of intestinal transplantation under FK 506 began after the suc-
cessful introduction of FK 506 as a rescue agent in patients for whom cyclo-
sporin therapy was ineffective (14). Transplantation under FK 506 was then 
adopted as a primary form of treatment for liver, kidney, heart, and lung 
recipients (15). 
The experimental results of intestinal transplantation were encouraging 
(16). A clinical trial demonstrated the feasibility and consistent success of 
intestinal transplantation, whether isolated or in combination with other or-
gans. In fact, isolated intestinal transplantation proved as efficacious as combi-
nation transplants. Furthermore, the procedure was easier to perform and fol-
lowed a less complicated postoperative course (17). This report is based on the 
information gathered from the intestinal transplantation trial under FK 506 at 
the University of Pittsburgh. 
INDICATIONS 
The generic indication for intestinal transplantation is intestinal failure, which 
is defined as the inability to maintain nutrition through the enteral route due to 
loss of native intestine absorptive surface or function. Loss of absorptive 
surface (short gut syndrome) is by far the more common of the two main 
causes of intestinal failure. In children, this was most frequently due to intesti-
nal resection following necrotizing enterocolitis, gastroschisis, volvulus, and 
intestinal atresia (18). Pseudoobstruction and generalized Hirschprung's dis-
ease were other indications, even though the intestine is anatomically intact. 
In adults referred to us for transplantation, the leading cause of Sh0l1 gut 
syndrome was Crohn's disease, followed by thrombotic disorders and trauma 
(12). The most common cause of loss of function in adults when intestine was 
present was pseudoobstruction, followed by radiation enteritis. 
The liver needs to be replaced only if associated severe liver disease or an 
inborn error correctable with liver transplantation is present. 
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PREOPERATIVE EVALUATION AND SELECTION OF THE 
APPROPRIATE OPERATION 
In addition to precise knowledge of the underlying disease, the entire gastroin-
testinal (GI) tract must be mapped in detail to decide which organs need to be 
replaced. Endoscopy, GI contrast studies, motility studies, and angiography 
are frequently used for this purpose. 
The condition of the native liver must be assessed to determine whether 
transplantation is necessary. When in doubt, a liver biopsy should be per-
formed. The presence of deep jaundice, severe hepatomegaly, and/or portal 
hypertension indicates that the liver must be replaced. Extensive fibrosis and 
cholestatic injury also point to irreversible damage and therefore require trans-
plantation. In both cases, the liver and other organs needed for transplant 
should be obtained from the same donor. 
In borderline cases, lack of data makes judgement more difficult. Mild 
jaundice may be reversible with successful intestinal transplantation, as we 
have seen once in our series. In the case of thrombotic disorders, natural 
anticoagulant deficiencies-in particular protein C, protein S, and anti-
thrombin III deficiency-should be systemically evaluated. These proteins are 
largely produced in the liver. Therefore, replacing the liver with a phenotypi-
cally normal liver will correct these problems because they are of hepatic 
ongm. 
Often one can determine which organ cluster needs to be transplanted, or 
whether the intestine alone will suffice, only after a thorough exploration of 
the organs during the operation. The donor surgeons are asked to bring back 
the entire multi visceral graft whenever possible, thereby exploiting the flexible 
cluster concept of removing extraneous organs when the abdominal explora-
tion is completed. 
CONTRAINDICATIONS 
Unless they are totally resectable with the transplant, infections and malignan-
cies are absolute contraindications. The investigative nature of these trans-
plants makes patients in extremis poor candidates, although humanitarian in-
stincts have sometimes prevented their exclusion. A combination of inferior 
vena cava and portal vein thrombosis, particularly in the context of previous 
surgery, has proven extremely difficult to handle technically and thus repre-
sents a high surgical risk. Multiple previous laparotomies complicate the pro-
cedure but do not constitute a contraindication to transplantation. Narcotic 
dependence is common among these patients, and rehabilitation before trans-
plantation is strongly recommended. 
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DONOR SELECTION 
Heart-beating cadavers with normal intestines are used as donors. They must 
have the same ABO blood type rto avoid humoral graft versus host disease 
(GVHD) complications] and be approximately the same size as the recipient. 
Histocompatibility locus antigen (HLA) matching is random. If the recipient is 
seronegative for cytomegalovirus (CMV) and the donor is CMV-positive, he 
or she could contract severe CMV -graft enteritis, despite the use of acyclovir 
and Ganciclovir (DHPG) prophylaxis. However, these donors cannot be ex-
luded in the case of children, given the scarcity of available grafts. Fortunately, 
most pediatric donors are CMV seronegative. 
In multiple organ recovery procedure, the heart, lungs, and kidneys are 
usually removed for transplantation in other patients. University of Wisconsin 
(Belzer) safely preserves the graft for at least 10-12 h. The graft is not 
subjected to immunoalteration with OKT3 pretreatment or by any other means. 
The organ supply for isolated intestinal grafts from cadaveric donors is cur-
rently plentiful. In the future, however, transplantation of intestinal segments 
from living related donors may be an attractive option because the segments 
may be immunologically more compatible. 
Figure I Isolated intestinal transplant. 
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RECIPIENT PROCEDURES 
Solitary Intestine 
When performing abdominal exploration and resection of the specimen, sur-
geons almost always must contend with adhesions and scars from multiple 
previous laparotomies. Careful dissection and hemostasis is therefore import-
ant to ensure successful transplantation. The infrarenal abdominal aorta is 
usually the source of arterialization of solitary intestinal grafts or of intestine 
combined with other viscera. The venous outflow of the isolated grafts is 
directed into the native portal system whenever possible, although some inves-
tigators have proposed drainage into the systemic venous circulation as an 
alternative and technically more expedient approach. However, drainage into 
the portal system is feasible almost without exception (19) (Figure 1). This 
method is preferable to systemic drainage because it does not produce an Eck 
fistula (portaprival) effect on the liver (20). 
Figure 2 Resection of liver with preservation of the native inferior vena cava (a portocaval shunt 
has been constructed). 
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Multiple Organ Grafts 
In combined liver-intestinal and multi visceral grafts, the native liver is 
stripped from the native vena cava, which remains intact (Figures 2 and 3). In 
combined liver-intestinal transplantation, an end-to-side portocaval shunt is 
performed to drain the retained host splanchnic organs via the native portal 
vein during the intraoperative time when the venous outflow is blocked. Out-
flow of the graft is accomplished by anastomosing the host and graft inferior 
vena cava with the piggyback technique (21) (Figure 4). If the anatomical 
situation is favorable, the portocaval shunt performed at the beginning of the 
operation to prevent venous stasis in the native organs is taken down after the 
graft is revascularized. The native portal vein is then anastomosed to the side 
of the donor portal vein to maintain complete hepatopetal f10w of the portal 
blood from both the graft and the retained host viscera. In some cases, a 
technically perfect portoportal anastomosis of this type cannot be performed 
(usually as a result of size discrepancy), and the previously constructed porto-
caval shunt that drains the native organs is left in place. 
Gastrointestinal continuity is established with conventional techniques. A 
stoma is constructed using the graft that provides venting and allows physi-
Figure 3 Multivisceral transplant. 
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cians easy access when perfomling endoscopies and biopsies. The stoma is 
closed when the graft stablizes and frequent endoscopies are no longer neces-
sary, usually several months after transplantation. In liver-intestinal clusters, 
the donor bile duct is drained into a Roux en Y loop, which is constructed 
using donor jejunum (Figure 4). 
PREVENTION, MONITORING, AND TREATMENT OF 
REJECTION 
Rejection is the most common complication of intestinal transplantation, oc-
curring in most clinical cases. Immunosuppression is based on FK 506, which 
is administered intravenously (0.1 mg/kg per day) immediately after the opera-
tion and then orally (0.3 mg/kg per day) when tolerated. The dose is decreased 
if nephrotoxicity occurs or if FK plasma levels are greater than 3 ng/ml and is 
increased if the recipient rejects the transplant. An intravenous infusion of 
PGE] given for five days after transplantation is considered weakly im-
munosuppressive and thought to reduce nephrotoxicity. Administration of a 
bolus of prednisolone at the time of transplantation is followed by a high dose 
(200 mg) that is tapered to a maintenance dose of 20 mg over 5 days. Tapering 
Fi/;ure 4 Combined liver-intestinal transplant. 
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of the steroid dosages may continue until they can be stopped. Steroid discon-
tinuation is particularly important for children because these hormones ad-
versely affect growth. However, weaning children off steroids must be done 
with great caution. 
Clinical signs of rejection include fever, graft dysmotility [low or (more 
often) high stomal output], and changes in stoma color. Other common com-
plications such as infection and ischemic injury have the same clinical presen-
tation. Endoscopy with multiple mucosal biopsies under vision is the best 
means by which to confirm or refute a diagnosis of rejection. Surveillance 
endoscopies and biopsies through the stoma are usually performed twice a 
week for one month after transplantation and once a week for 1-2 months 
thereafter. Endoscopic signs of rejection include erythema and induration of 
the graft, which is covered with exudate or pseudomembranes if rejection is 
severe. 
Histologically, acute rejection presents as a widening of the lamina propria 
with inflammatory cells, primarily blastic lymphocytes accompanied by 
smaller lymphocytes. eosinophils, and macrophages with or without neutro-
phils. Epithelial cell necrosis, goblet and Paneth cell depletion, and epithelial 
regenerative changes also occur. More severe rejection presents with focal 
ulceration, which can evolve into mucosal sloughing. Treatment of rejection 
varies according to its severity. Augmentation of the baseline FK 506 and 
steroid dose is sufficient to treat mild rejection, whereas steroid bolus and/or a 
temporary period of high doses of prednisolone are required for moderate or 
severe rejection. If this medication proves ineffective, antilymphocyte globulin 
(ALG) may be adminstered as a last resort. Repeated endoscopies and biopsies 
are used to monitor treatment effectiveness. 
Repeated severe acute rejections can lead to chronic rejection characterized 
by mterial occlusive diseasc. A full thickness biopsy or arteriography must be 
performed to confirm this diagnosis. Mucosal biopsy shows distortion of the 
mucosal architecture with villous blunting, widening, and fibrosis of the lam-
ina propria; loss of goblet and Paneth cells; focal ulceration; and metaplasia. 
Although hyperacute or humoral rejection may occur in experimental animals, 
neither has been detccted in clinical cases. Five transplants of isolated (n = 1) 
and combined (n = 4) intestinal grafts have been performed in the presence of 
a positive cytotoxic cross match with no adverse consequences. 
In our series, definite GVHD occurred only once, in a patient whose im-
munosuppressive therapy was greatly reduced in the setting of surgical infec-
tion. Subclinical GVHD, manifested as transient skin rash with fever of un-
known etiology, has been suspected in intestinal transplantation patients but 
has not been well documented. Rejection of the liver is diagnosed and treated 
as in liver transplantation. 
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PREVENTION, MONITORING, AND TREATMENT OF 
INFECTION 
Infection is the second most common complication of intestinal transplanta-
tion. Careful attention must be paid to the details of surgical technique because 
major contamination during surgery in the presence of immunosuppression 
will most likely result in a surgical infection. Failure of a single anastomosis 
will also lead to infection, which is usually the first of several complications 
leading to death. 
Both donor and recipient undergo enteral decontamination and receive 
intravenous antibiotic prophylaxis. The recipient receives enteral treatment for 
4-6 weeks postoperatively, but intravenous antibiotics are administered for 
only 5-7 days unless a specific reason warrants continued dosages. Even if 
surgical technique is perfect, the recipient runs a high risk of bacterial or 
fungal infection from the intestinal graft because rejection, ischemic injury, or 
a viral infection can open the mucosal barrier to enteral microorganisms. The 
resulting septicemia (translocation) can cause contamination of indwelling 
venous and arterial lines, which need to be cultured and replaced frequently. 
These lines must be used for long periods during postoperative convalescence 
and can consequently act as the primary source of infection. 
All body fluids are frequently cultured. In particular, stool cultures are 
performed twice a week for 6-8 weeks posttransplant, and if bacterial growth 
is significant (> 106 colonies/rnl), the enteral decontamination is modified 
accordingly. Low-dose trimethoprim-sulfamethoxazole is used to prevent 
pneumocystis pneumonia. However, since no prophylaxis effectively combats 
viruses, the best strategy is to avoid excessive immunosuppression. Intrave-
nous DHPG and oral or intravenous acyclovir are administered liberally for 
cytomegalovirus and Epstein-Barr virus prophylaxis, but they seem only to 
postpone and perhaps lessen the severity of these infections, rather than pre-
vent them. 
Infection must be recognized early and treated promptly. All histological 
specimens obtained in an infection workup are sent for viral cultures, stains, 
and polymerase chain reaction (PCR) to search for viruses. If a virus is identi-
fied, treatment begins immediately. Although specific treatment for some vi-
ruses such as respiratory syncytial virus and adenovirus is not available, dras-
tic reduction of immunosuppression can ameliorate viral infections. 
NUTRITION 
A feeding jejunostomy or gastrostomy is routinely placed at the time of trans-
plantation. Enteral nutrition begins as soon as intestinal motility is established 
and increased as tolerated. Formulas used include Vivonex TEN®, Pepta-
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men®, and Modified Compleat®. The physician may treat the presence of 
glucose in the stool and/or high stomal output in the absence of rejection or 
infection by reducing the rate of enteral feedings and using antidiarrheal drugs. 
Intravenous nutrition is administered liberally, gradually decreased, and 
stopped only when the enteral feedings satisfy the nutritional needs of the 
patient. 
Adult patients usually resume their normal eating habits quickly. Children, 
on the other hand, may refuse to eat, either because they never learned how 
or because they are afraid to do so. Teaching them how to eat is a difficult 
task, although it is easier if they were already ingesting food prior to transplan-
tation. 
ASSESSMENT OF GRAFT FUNCTION 
Simple clinical observations such as maintenance of body weight during the 
course of enteral feedings, serum albumin, and enteral output playa valuable 
role in the assessment of graft function. FK 506 plasma levels are a poor man's 
test of its absorptive capacity, and the absence of sugar or presence of trace 
quantities in the enteral output indicates good carbohydrate absorption. The 
presence of greater amounts of sugar indicates an inability to tolerate the 
feedings. 
The D-xylose absorption test provides a better assessment of carbohydrate 
absorption, which is depressed for four weeks after transplantation and nor-
malizes over several months. Improvement of D-xylose absorption over time 
is a positive sign. Gradual deterioration, on the other hand, has been associated 
with chronic rejection. Moderate or severe graft rejection and/or cytomegalo-
virus infection depress the D-xylose absorption curve. However, the results 
must be interpreted cautiously in cases of delayed gastric emptying, intestinal 
dysmotility, and impaired renal function because these also have multifactorial 
etiologies. 
The level of fat absorption usually falls below normal but rarely reaches 
levels at which steatorrhea is produced. Serum level measurements of vitamins 
A, D, and E and 72-h stool fat excretion measure fat absorbtion. Indirect 
methods such as serum albumin and prealbumin as well as anthropometric 
measurements are usually used to calculate protein absorption levels. 
Motility can be grossly assessed either by the enteral output or with radio-
logical studies. Motility studies are performed periodically to evaluate the 
motility patterns of the graft components. Assessment of the liver function is 
as in liver transplantation. 
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RESULTS 
Forty-five intestinal transplants were performed at the University of Pittsburgh 
under FK 506 immunosuppression between May 1990 (when the program 
started) and April] 993. Follow up is provided through June 1, 1993. Twenty-
three adults (mean age 33.2 years, range 19-58 years) and 22 children (mean 
age 3.5 years, range 0.5-15.5 years) participated in the program. Two patients 
died on the operating table during attempted multivisceral transplantation. 
Fifteen patients underwent isolated intestinal transplantation, 21 underwent 
combined liver-intestinal transplantation, and 7 underwent multivisceral trans-
plantation. The large bowel was included in the graft of the last 13 patients in 
this series. 
Two retransplantations were performed: one solitary intestinal and one 
combined liver-intestinal. Cumulative one-year patient survival was 82% 
(adults: 89.4%; children: 75.6%) and graft survival was 73% (adults: 79.3%; 
children: 68%). One-year patient survival for isolated intestinal transplantation 
and combined transplantation was 90.9 and 76.2%, respectively. One-year 
graft survival was 70.0 and 72.7%, respectively. Of the seven recipients of the 
multiviseeral transplant procedure, six are alive. No retransplantations were 
performed in this group. 
Eleven patients died posttransplantation: five of acute rejection and sepsis 
before (n = 3) or after (n = 2) removal of their grafts, three of sepsis due to 
technical failure. and the other three of lymphoproliferative disease (n = 1), 
pneumonia (n = I), and TPN catheter-related pulmonary embolus (n = 1). 
The frequcncy and severity of acute rejection of the intestine did not vary 
between the recipients of solitary vs combination grafts. In combined liver-in-
testinal grafts, the frequency and severity of acute liver rejection was approxi-
mately the same as that reported by us and others in recipients of isolated liver 
grafts. Patients who received an isolated graft tolerated enteral feedings and 
became TPN-independent sooner than did combined transplant recipients. 
Mean intensive care unit and hospital stay were also shorter for isolated 
intestinal graft recipients. 
Three recipients of a combined liver-intestinal graft developed 
lymphoproliferative disease, resulting in one fatality. Thirty-two patients are 
still alive, of which 25, including the longest-surviving patient (3 years), are 
totally free of TPN and follow an unrestricted, regular diet. Six patients still 
require partial TPN support, but only one remains fully dependent on TPN. 
CONCLUSION 
Transplantation of the intestine, whether alone or in combination with other 
intraabdominal organs under FK 506 immunosuppression, yields results com-
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parable to those obtained from more commonly performed transplantations. 
This procedure represents a reasonable alternative for the treatment of intesti-
nal failure, provided that the complexity of patient care and the commitment 
required to provide this care are taken into account. 
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